Senti Bio FY2025 net loss $61.4M; SENTI-202 gets RMAT, Phase 1 data encouraging

Senti Biosciences, Inc.

Net loss $61.4M for FY2025 ($2.73/share); Q4 loss $14.5M ($0.53/share).
Cash and equivalents $16.4M as of December 31, 2025.
SENTI-202 received RMAT designation for relapsed/refractory AML; updated Phase 1 data show encouraging responses and safety.
R&D expenses $37.6M full year; G&A expenses $26.2M full year, down in Q4 YoY.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Senti Biosciences, Inc. reported the year ended December 31, 2025 results: net income Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share, EPS $2.73 per share.

Period: the year ended December 31, 2025
Net income: Net loss ... for the full-year 2025 was $61.4 million, or $2.73 per share
EPS: $2.73 per share
Result: reported results

Exact text from the filing

Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

Senti Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-021578

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.